Evidence map›Paper›PMID 40389636›Full record

ArticleHypertension research : official journal of the Japanese Society of Hypertension2025

Comparison between sacubitril/valsartan and thiazide diuretics among patients with uncontrolled hypertension in Japan.

Kazuo Kobayashi, Mari Sotozawa, Keiichi Chin, Hideo Shimura, Kyoji Chiba, Shun Ito, Toshinao Tsuge, Hiroyuki Sakai, Takayuki Furuki, Atsushi Matsuzaki and 10 more

Abstract readComparative Study
PubMed Publisher
In one paragraph

Article in Hypertension research : official journal of the Japanese Society of Hypertension, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

20 authors.

Kazuo KobayashiCommittee of Hypertension and Kidney disease, Kanagawa Physicians Association, Yokohama, Kanagawa Prefecture, Japan. k-taishi@xc4.so-net.ne.jp.
Mari SotozawaDepartment of Medical Science and Cardiorenal Medicine, Yokohama City University Graduate School of Medicine, Yokohama, Japan.
Keiichi ChinCommittee of Hypertension and Kidney disease, Kanagawa Physicians Association, Yokohama, Kanagawa Prefecture, Japan.
Hideo ShimuraCommittee of Hypertension and Kidney disease, Kanagawa Physicians Association, Yokohama, Kanagawa Prefecture, Japan.
Kyoji ChibaDepartment of nephrology, Yokohama Sakae Kyosai Hospital, Yokohama, Japan.
Shun ItoCommittee of Hypertension and Kidney disease, Kanagawa Physicians Association, Yokohama, Kanagawa Prefecture, Japan.
Toshinao TsugeCommittee of Hypertension and Kidney disease, Kanagawa Physicians Association, Yokohama, Kanagawa Prefecture, Japan.
Hiroyuki SakaiCommittee of Hypertension and Kidney disease, Kanagawa Physicians Association, Yokohama, Kanagawa Prefecture, Japan.
Takayuki FurukiCommittee of Hypertension and Kidney disease, Kanagawa Physicians Association, Yokohama, Kanagawa Prefecture, Japan.
Atsushi MatsuzakiCommittee of Hypertension and Kidney disease, Kanagawa Physicians Association, Yokohama, Kanagawa Prefecture, Japan.
Shinichi NakajimaCommittee of Hypertension and Kidney disease, Kanagawa Physicians Association, Yokohama, Kanagawa Prefecture, Japan.
Nobukazu TakadaCommittee of Hypertension and Kidney disease, Kanagawa Physicians Association, Yokohama, Kanagawa Prefecture, Japan.
Hareaki YamamotoCommittee of Hypertension and Kidney disease, Kanagawa Physicians Association, Yokohama, Kanagawa Prefecture, Japan.
Hiroshi TakedaCommittee of Hypertension and Kidney disease, Kanagawa Physicians Association, Yokohama, Kanagawa Prefecture, Japan.
Hiromichi WakuiDepartment of Medical Science and Cardiorenal Medicine, Yokohama City University Graduate School of Medicine, Yokohama, Japan.
Takamasa IwasawaCommittee of Hypertension and Kidney disease, Kanagawa Physicians Association, Yokohama, Kanagawa Prefecture, Japan.
Togo AoyamaDepartment of Nephrology, Kitasato University School of Medicine, Sagamihara, Japan.
Masao ToyodaDivision of Nephrology, Endocrinology and Metabolism, Department of Internal Medicine, Tokai University School of Medicine, Isehara, Japan.
Kouichi TamuraCommittee of Hypertension and Kidney disease, Kanagawa Physicians Association, Yokohama, Kanagawa Prefecture, Japan.
Akira KanamoriCommittee of Hypertension and Kidney disease, Kanagawa Physicians Association, Yokohama, Kanagawa Prefecture, Japan.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Although renin-angiotensin system (RAS) inhibitors and calcium channel blockers are widely used to treat hypertension in Japan, <10% of patients use thiazides. This study aimed to evaluate differences in the efficacy and safety of sacubitril/valsartan and thiazide diuretics. Patients with poor blood pressure (BP) control, despite combination treatment with RAS inhibitors and calcium channel blockers, were included in the study. Patients treated with thiazides (THZ group, n = 306) and those who switched from RAS inhibitors to sacubitril/valsartan (SacVal group, n = 433) were compared. Propensity score analysis with inverse probability weighting was performed. A significantly higher target BP achievement rate was observed in the SacVal group than in the THZ group (4 months, 37% vs. 26%, p < 0.001). In a general linear mixed model, significant decreases in office and home BP were observed in both groups (p < 0.001); however, no significant interaction effects were observed between the drug type and time course. Discontinuation of the treatment by adverse events was significantly more frequent in THZ group (10%) than in SacVal group (3%), with a hazard ratio [95% confidence interval] of 3.47 [1.78, 6.76] (p < 0.001). In the model using the propensity score, compared with THZ group, significantly lower levels of office and home systolic BP, uric acid, glycated hemoglobin A

Indexed as

AminobutyratesAngiotensin Receptor AntagonistsAntihypertensive AgentsHypertensionSodium Chloride Symporter InhibitorsTetrazolesValsartanAgedBiphenyl CompoundsBlood PressureDrug CombinationsFemaleHumansJapanMaleMiddle AgedAminobutyratesAngiotensin Receptor AntagonistsAntihypertensive AgentsBiphenyl CompoundsDrug Combinationssacubitril and valsartan sodium hydrate drug combinationSodium Chloride Symporter InhibitorsTetrazolesValsartanCombination treatmentSacubitril/valsartanThiazide diuretics

Identifiers

PMID40389636

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.